-- Preview Email Newsletter
| Public Policy Tipoffs Involving Delaware Newsletter for 2026-02-22 ( 2 items ) |
|
Calquence Plus Venetoclax Approved in the US as First All-Oral, Fixed-Duration Combination for Patients With Chronic Lymphocytic Leukemia in the 1st-Line Setting (10)
WILMINGTON, Delaware, Feb. 21 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
CALQUENCE(R) plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
CALQUENCE plus venetoclax demonstrated statistically significant and clinically
meaningful improvement in progression-free survival vs. chemoimmunotherapy, with
77% of patients progression free at three years in AM more PR
Global Lesson in Purpose: U.S. Samsung Solve for Tomorrow Students Recognized at Olympic Winter Games Milano Cortina 2026 (10)
SEOUL, South Korea, Feb. 21 -- Samsung, a manufacturer of mobile devices and wearable tech to intelligent home appliances, issued the following news:
* * *
A Global Lesson in Purpose: U.S. Samsung Solve for Tomorrow Students Recognized at Olympic Winter Games Milano Cortina 2026
Samsung Electronics celebrated two U.S. Samsung Solve for Tomorrow alumni at the Olympic Winter Games Milano Cortina 2026, recognizing their selection as Global Solve for Tomorrow Ambassadors and marking a milestone m more PR
|
